June 1, 2017
REV.1 Engineering Team

Client Collaboration in Outsourced Medical Device Development

We were thinking about the expression, “When I tell you to jump, you say, ‘How high?’” The intent of this expression is clearly “Do what you’re told,” and we often encounter clients that approach outsourcing in the same fashion. Rather than approaching a partner company from a collaborative standpoint, they believe they have to control every step. Exerting excessive control is usually a response to managing the unknown. Often a client’s fears of entering a […]
June 20, 2017

REV.1 Engineering’s Program Management

REV•1 Engineering’s program management team is inseparable from the engineering team. They have worked together for years in our unique medical device product development ecosystem. As a well-oiled team, they do not need weeks to integrate with your company and discuss the plan. Our ecosystem to create and implement your product development plan is ingrained. They know the right person for every role, and resource each step in accordance with the plan. REV•1 program managers […]
June 15, 2017

Why REV.1 Engineering is a Top Choice for Your Medical Device Development

We’re so confident and ready to roll, that when you say “yes,” we begin working on your innovative medical device that very day. While REV•1 always creates a plan to take your medical through commercialization, your contract only needs to go to product feasibility, limiting your up-front risks and flushing out design and clinical risks early. In one phone call, you will immediately access REV•1 ’s expert R&D team: • REV•1 is owner operated and […]
June 11, 2017
Funding for medical device development

REV.1 Engineering and Your Medical Device Funding Plan

REV•1 Engineering’s medical device development typically gets clients to CE and FDA approvals before it is necessary to build a commercialization team. Most of our successful clients have not needed to hire full-time employees, other than C-level, prior to series C funding. This creates a very fast and capital-efficient model to get to a potential acquisition or confident funding of commercialization. REV•1 also understands that there are many “customers” in the commercialization chain. From health […]
Schedule a Conversation
Contact Us